Pharma AI Weekly #33: Mayo Clinic’s AI with Microsoft & Cerebras, Menarini & Insilico AI-Powered Oncology Deal and Panakeia’s Cancer AI Profiling Tool
Welcome to Pharma AI Weekly!
At ctcHealth, our team of experts understands that keeping up with AI advancements is crucial. That's why we're here to keep you informed and empowered!
Each week, our team carefully selects the most pertinent AI-related articles from the pharmaceutical industry, providing concise summaries and direct links to these valuable resources.
We invite you to Subscribe Here and discover how AI is transforming our industry.
Now, let’s explore three key AI developments impacting our industry this month:
Pharma AI Weekly Key Insights
1. Mayo Clinic Partners with Microsoft and Cerebras for AI-Powered Personalized Medicine
Published: January 15, 2025
Mayo Clinic has formed transformative collaborations with Microsoft Research and Cerebras Systems to develop generative AI models aimed at enhancing patient care, accelerating diagnostics, and improving accuracy.
Key Highlights:
Radiology Innovation with Microsoft: The collaboration focuses on creating multimodal foundation models that integrate imaging (e.g., chest X-rays) with textual clinical data. This system automates tasks like generating reports, evaluating tube placements, and detecting changes in radiographic images.
Genomic Breakthrough with Cerebras: A genomic foundation model has been developed using Mayo’s exome sequencing data and public genome datasets. This AI-powered model enhances diagnostic speed and accuracy, particularly in diseases like rheumatoid arthritis, enabling faster and more targeted treatments.
Proven Performance: Cerebras’s advanced computing made it possible to train the genomic model on massive datasets efficiently, achieving superior benchmark results.
Why This Matters:
Improved Patient Outcomes: These models enable faster, more accurate diagnosis and targeted treatment strategies.
Operational Efficiency: AI automates time-consuming processes, allowing clinicians to focus on critical decision-making.
Precision Medicine Advancements: The genomic model supports the development of therapies tailored to individual patient needs, addressing complex diseases like rheumatoid arthritis.
" Multimodal foundation models hold immense promise in tackling significant roadblocks across the radiology ecosystem. The innovations we're creating with Microsoft Research will help unlock valuable insights for the future of medical imaging to improve how radiologists work and how patients are cared for.Focusing on chest X-ray reports, Mayo's clinical teams and Microsoft researchers will collaborate to advance the state-of-the-art in multimodal AI radiology, helping bring innovation to real-world application faster and at scale, which is key to making exemplary healthcare more accessible." - Matthew Callstrom, M.D. Ph.D., chair of Mayo Clinic Radiology in the Midwest and medical director for Generative AI and Strategy
Read More: Mayo Clinic partners with Microsoft Research and Cerebras to revolutionize AI in healthcare
Additional Resources:
2. Menarini and Insilico Medicine Partner for Next-Gen Cancer Therapy
Published: January 10, 2025
The MENARINI Group, through its subsidiary Stemline Therapeutics, has entered into an exclusive licensing agreement with Insilico Medicine to develop and commercialize a preclinical small molecule for solid tumors. The molecule was designed using Insilico’s Chemistry42 AI platform and has shown broad anti-tumor activity in preclinical studies.
Key Highlights:
Promising Oncology Molecule: Developed with AI, the molecule addresses high unmet needs in oncology, showing activity across multiple solid tumor types.
Significant Investment: Stemline will pay Insilico $20 million upfront, with milestone payments exceeding $550 million. This highlights the confidence in AI-enabled drug discovery.
Proven Collaboration: This agreement follows a prior partnership between the two companies for a breast cancer treatment candidate, reinforcing their shared commitment to advancing cancer therapies.
Why This Matters:
Accelerated Drug Development: AI-driven platforms like Chemistry42 reduce the time and cost required to create and test innovative treatments.
Addressing Unmet Needs: The molecule targets cancers with limited treatment options, offering hope for improved outcomes.
Strategic Alliances: Collaboration between Menarini and Insilico underscores the growing reliance on AI to innovate in drug development.
"We are thrilled to enter our second collaboration with Insilico Medicine, a leader in the field of generative AI, for a highly selective and potentially best-in-class small molecule targeting a broad range of cancers.This asset will help us enter into new areas of high unmet need, expanding the tumor areas where we can help cancer patients with ground-breaking therapies." - Elcin Barker Ergun, CEO of the Menarini Group
Read More: Menarini Group signs licensing deal with Insilico for promising cancer treatment
Additional Resources:
3. Panakeia’s AI Tool for Colorectal Cancer Profiling
Published: January 15, 2025
Panakeia has introduced PANProfiler Colon, an AI-driven solution designed to rapidly detect Microsatellite Instability (MSI) and mismatch repair deficiency (dMMR) from Hematoxylin and Eosin (H&E)-stained images. This software is a key addition to Panakeia’s multi-omic biomarker profiling platform.
Key Highlights:
Rapid and Accurate Profiling: PANProfiler delivers MSI/dMMR results in minutes, replacing traditional methods with faster, digital analysis. This ensures timely, accurate diagnosis critical for colorectal cancer and Lynch syndrome detection.
Clinical Applications: The software is deployed across UK hospitals, with applications in patient screening and clinical trials. MSI/dMMR status is vital for guiding personalized immunotherapy decisions.
Global Precision Medicine Impact: PANProfiler Colon follows the success of PANProfiler Breast and reflects Panakeia’s commitment to making precision medicine accessible worldwide.
Why This Matters:
Accelerated Diagnostics: Faster biomarker identification enables earlier intervention and treatment.
Enhanced Patient Care: Accurate profiling ensures that patients receive treatments tailored to their specific biomarker profiles.
Scalability: The digital nature of PANProfiler supports its adoption in diverse healthcare settings, reducing costs and improving efficiency.
Read More: Panakeia launches AI-driven PANProfiler Colon for rapid cancer profiling
Additional Resources:
Did you find this helpful?
If you enjoy the read, subscribe on LinkedIn to this weekly newsletter to stay updated on Pharma AI! Feel free to contact us at ctcHealth and explore how you can harness the power of AI in your sales operations.
Best regards,
The ctcHealth Team
About ctcHealth
Founded by Thomas Mrosk in 2024, ctcHealth specializes in AI Automation Consulting and AI Coaching services designed to transform the sales process in the healthcare industry.
Our diverse team combines pharmaceutical expertise and cutting-edge AI to create tailored solutions that meet today's market demands.